As a SME, we have innovation at our heart. In a fast moving field, we strive to incorporate the latest scientific and technological advances into our products and services. To achieve this, we maintain a rich pipeline of exploratory research projects as well as engage in research consortia with leading academic groups.

We are always interested to discuss our ongoing research projects, start new partnerships or design joint grant applications with you.

Interested? Let us know!

Contact us

TRAIN: Marie Sklodowska Curie ITN Project Grant

We are proud member of this European training network that was brought together in the context of the medical need to tackle the clinical consequences of obesity-related diseases more holistically. Dysregulation of common molecular pathways that govern the physiological functions of adipocytes, immune cells and prostate epithelial cells have been reported in immuno-metabolic diseases (e.g. obesity) and several cancers. The goals described in this project will investigate regulators of these pathways, focusing on tribbles (TRIB) proteins, proteins recently described to be a family of pseudokinases, which have a key role in controlling immunity, metabolism and cancer. These proteins will serve as prototypical examples for integrative metabolocentric cancer research. Specifically, TRIBs are envisaged to contribute directly to the development and progression of prostate cancer (PCa), the prognosis of which is substantially worsened in individuals with immuno-metabolic disease.

The overall objective of this multidisciplinary research-training program will be to uncover cell-specific aspects of TRIB-mediated control of immuno-metabolism and their impact on PCa progression. We will approach this by integrating cell biology and sophisticated in vivo models of both immuno-metabolic disease and PCa, complemented by specialist human disease biobank materials, cutting-edge genomics approaches, and a drug discovery pipeline. This will be carried out by an alliance of leading academic research groups and specialist SMEs with complementary backgrounds in inflammation, adipose tissue (AT) biology, tumorigenesis, genomics, translational models of human disease, medicinal chemistry, and drug discovery.

At Intelligent Pharma, TRIB proteins and related complexes will be modeled. Protein-protein docking will be applied to explain the regulation of this family of proteins within the context of their interactions.

EU EUROSTARS project: Pathway-Disco

Recent groundbreaking advances lead to a "GPCR" Nobel Prize in 2012 and have rendered many commonly employed GPCR drug discovery technologies obsolete. We want to be part of the next generation of GPCR discovery by developing technologies that define, and then lock single stabilized GPCR conformational states for both physical drug discovery and for in silico drug discovery. The goal of this project is to deliver disruptive physical and computational products/services based on these technologies. Intelligent Pharma is the partner responsible for performing the computational studies in this three party consortium.

GPCRs Pathway Disco leaflet - PDF [450 kb]

DIALCAT

Intelligent Pharma is project coordinator of the DIALCAT consortium of 17 companies, research institutes and hospitals. The main objective of this project is to study the occurrence of Alzheimer's disease in type 2 diabetes mellitus (DM2) patients.

There is robust epidemiological data showing that DM2 patients have a 2-3 times higher prevalence of severe cognitive impairment and Alzheimer's disease than non-diabetic people of the same age. This entails a serious social and health problem. This group generates a system health expenditure of approximately 5,500 million euros in Spain. In order to face this problem a multidisciplinary approach is required which will improve cost-efficiency and benefit. DIALCAT proposes a comprehensive approach that includes the development of an electronic dispenser monitor to assure that patients take the right medication at the right time. This device will be validated in a clinical observational pilot intervention study to improve metabolic control and to ensure adherence between medical and health conditions of the patients. The success of the project is based on a strong collaboration between all parties involved (clinicians, caregivers, patients and pharmacists) and has as ultimate goal to delay the onset of Alzheimer's disease which is directly linked to a social and economic return in investment.

Intelligent deployment system of scientific applications in the cloud (TSI-100104-2015-27)

Intelligent Pharma has been awarded an A.E.E.S.D. - Impulso Tecnológico grant by the Spanish Ministry of Industry (MINETUR) in order to develop new advanced computational chemistry technologies in the cloud.

This project consists of the development of an intelligent system to deploy scientific applications in the cloud. Computational chemistry technologies are based on work-flows. During this project, we will study, develop and validate a system to deploy such scientific work-flows using hybrid cloud computing systems i.e. combining our own internal super computational facilities with cloud-based environments such as Amazon EC2 and the Google Compute Engine. The technology to be developed will significantly enhance Intelligent Pharma’s productivity during in silico R&D research projects. The project started in July 2015 and will finish in June 2017.

Acción Estratégica de Economía y Sociedad Digital - Impulso Tecnológico (A.E.E.S.D. - Impulso Tecnológico), financiación procedente del Fondo Europeo de Desarrollo Regional (FEDER).